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ABSTRACT   
Background: This study investigates the role of ephrin receptor A3 (EphA3) in the pathogenesis of 
Multiple Myeloma (MM) and the effects of a selective target of EphA3 by a specific monoclonal 
antibody on bone marrow endothelial cells (ECs) of MM patients.  
Methods: EphA3 mRNA and protein were evaluated in ECs of MM patients (MMECs); in ECs of 
patients with monoclonal gammapathies of undetermined significance (MGECs) and of those with 
benign anemia (ECs controls). The effects of EphA3 targeting by siRNA or by the anti EphA3 
specific antibody on the angiogenesis was evaluated in vivo and in vitro. The antitumor activity of 
the antibody targeting EphA3 was measured in vivo in MM xenograft mice. 
Results: Compared to the other EC types, MMECs showed a high level of expression of EphA3 
both as mRNA transcript and protein. The EphA3 targeting by either siRNA or anti EphA3 
antibody impaired the MMECs angiogenesis-related functions both in vitro and in vivo. 
Importantly, a clear antitumor activity was demonstrated in NOD SCID mice injected with human 
MM cell line JJN3 and treated with EphA3 targeting antibody.  
Conclusions: EphA3 plays a critical role in MM angiogenesis; the anti EphA3 antibody inhibits 
this process in vitro and in vivo. EphA3 targeting could represent a novel strategy for the treatment 
of multiple myeloma patients.  
 
 
 
 
INDRODUCTION  
Multiple myeloma (MM) is a clonal disorder originating from post germinal center B cells that have 
undergone somatic hypermutation and immunoglobulin heavy-chain class switching. These cells 
typically locate in the bone marrow microenvironment that critically supports MM cell growth and 
survival.1 Particularly, angiogenesis plays a critical role in the MM pathophysiology and 
progression.2 Despite availability of several new therapeutic agents such as thalidomide, 
lenalidomide and bortezomib, MM remains incurable.3 Therefore, there is an urgent need to develop 
new agents targeting additional pathways relevant for MM cells maintenance to increase the 
spectrum of available therapies. In this setting, monoclonal antibodies against MM-specific cell 
surface antigens represent a promising therapeutic approach, which is however hampered by a lack 
of appropriate membrane target structures expressed across MM cells. 
A group of signaling molecules, the ephrins (Efn) and their receptors (Eph), has recently emerged as 
attractive therapeutic targets, since they control pathways which are critical for the development and 
maturation of myeloid and lymphoid cells. 4,5 
The Ephs belong to the largest family of receptor tyrosine kinases, divided in two subfamilies: the 
EphA and EphB according to the preferential ligand. Usually, EphA receptors interact with  
glycophosphatidylinositol (GPI)-anchored EfnAs, and EphB interact with transmembrane  EfnBs, 
although there are exception to this rule.6 Eph receptors have vital functions, including cell 
adhesion, migration and axon guidance, during development and homeostasis of many tissues. 7-10 
Compelling evidence also suggests that Eph-ephrin signaling plays several important roles in cancer 
development and progression. Expression of ephrin ligands and receptors is often reduced in 
advanced-stage tumors, and Eph-ephrin signaling regulates tumor growth, metastasis, and 
angiogenesis by altering cell proliferation, motility, invasion, and migration.11  
The overexpression of EphA3 has been demonstrated in some cancers, including lung cancers, 
melanomas, gastric carcinoma and leukemia. 12-15 EphA3 expression is known to be associated with 
B and T cell malignancies. 16,17 Recently Bryan et al. described EphA3 is highly expressed on the 
tumor-initiating cell population in glioblastoma multiforme18 and it is important in angiogenesis and 
prognosis of gastric and pancreatic carcinoma. 15,19 
No data are available in literature regarding the EphA3 expression in MM patients and its role in 
favoring MM malignant cell growth and in sustaining angiogenesis in MM microenvironment. 
Based on the original anti EphA3 monoclonal antibody IIIA412,20 a first-in-class engineered IgG1 
antibody targeting the EphA3 (KB004) was developed and it is now under phase I/II clinical trials 
for the treatment of EphA3 overexpressing hematological myeloid malignancies refractory to 
conventional treatment. 
Here we bring for the first time the proof of concept of the antiangiogenic efficacy of blocking 
EphA3 with highly-specific human antibody in vitro and in vivo, showing a potent anti-tumor 
activity in MM xenograft model in mice, which might have potential therapeutic applications. 
 
MATERIALS AND METHODS
Patients, Endothelial cells (ECs) and Plasma Cells  
The study was approved by the Ethics Committee of IRCCS-CROB (Prot 3725; 7-2-2008), all 
patients provided informed consent. BM primary ECs from control subjects, from MM (MMECs) 
and from MGUS (MGECs) patients were obtained and cultured as described.21 The patient 
information and the MMECs antigen phenotype are described in Supplemental Experimental 
Procedures and data are showed in Supplementary figure 1.kdskd 
The ATCC human myeloma cell lines, MM1S, U266, RPMI8226 and DSMZ JJN3 cells were 
cultured in RPMI 1640 medium (Gibco) containing 10% fetal calf serum and 1% antibiotics 
(Gibco) and growed at 37°C under 5%CO2/95% humidified air. 
 
Absolute real-time  PCR ( RT-PCR) 
RNA from MMECs, MGECs, normal ECs was extracted using Rneasy mini kit (Qiagen, Hilden, 
Germany). First strand cDNA was synthesized using random hexamers and trascriptor first strand 
cDNA kit (Roche, Molecular Biochemicals, Mannheim, Germany). Absolute RT-PCR was carried 
out using Taqman assay (Perkin-Elmer–Applied Biosystems, Massachusetts USA). Cycling 
conditions are listed in Supplemental Experimental Procedures. 
 
Western blot (WB), Fluorescence-activated cell sorting (FACS) analysis, Immunofluorescence-
confocal laser scanning microscopy (IF) and immunohistochemistry(IHC) 
For WB, we used anti EphA3 (Abcam, Cambridge, UK) and anti-β-actin (Sigma-Aldrich, St. Louis, 
MO, USA).  
For FACS, a phycoerythrin (PE)-labeled anti-CD105 antibody (Beckman Coulter, Brea, CA, USA), 
anti-EphA3 (AbCam) and isotype matched control antibodies were used.  
For IF, anti-EphA3 antibody (AbCam), then goat anti-mouse Alexa Fluor 488 (Invitrogen) were 
used. 
BM sections of MM patients were stained with anti EphA3-specific monoclonal antibody SL2  
(kindly provided by KaloBios Pharmaceuticals, San Francisco, CA, USA). Tissue sections were 
counterstained with Mayer’s hematoxylin solution (H&E). All preparations are indicated in 
Supplemental Experimental Procedures. 
 Small interfering RNA (siRNA)  
MMECs (4×105) were transiently transfected with EphA3–siRNA or control siRNA (Silencer 
Selecter siRNA Ambion, Lifetechnologies) 5 nM or with the transfection reagent alone 
(Lipofectamine, RNAiMAX siRNA transfection reagent, Lifetechnologies) for 5 days and 
submitted to the followed functional studies.   
Treatment of MMECs with antibodies 
MMECs were treated with anti EphA3 antibody (chIIIA4) or an irrelevant Ab at 7,5 ug/ml or with 
Dulbecco's Modified Eagle Medium (DMEM; Gibco, Milan, Italy) alone and submitted to the 
followed functional studies.   
Functional studies 
Adhesion: One×104 siRNA MMECs were plated in DMEM on fibronectin-coated 96-well plates in 
triplicate for 30 min, fixed with 4% paraformaldehyde and quantified by the crystal violet assay at 
595 nm in a Microplate Reader (Molecular Devices Corp., Sunnyvale, CA, USA).  
Chemotaxis: Five×104 siRNA MMECs as above were tested in Boyden microchamber assay 
towards 1.5% serum medium with Vascular endothelial growth factor (VEGF 10 ng/ml, Sigma 
Chemical Co.) and fibroblast growth factor 2 (FGF-2; 10 ng/ml, Peprotech Inc., Rocky Hill, NJ, 
USA) as chemoattractants. After 8 h at 37°C, the migrated cells were fixed, stained and counted by 
the EVOS inverted microscope (Euroclone) at X400. 
Scratch Wound Healing Assay: MMECs (2 × 104 cells/well) were seeded in 96-well plates, 
cultured to confluence and then scraped with a pipette tip to generate scratch wounds. Cells were 
incubated at 37 °C for 24 h with the medium alone or containing anti EphA3 or isotype Ab control. 
Images were captured using a Nikon Eclipse TE2000-5 microscope. Four selected field of images 
were captured in each sample, and the wound areas were estimated by Nikon NIS-Elements 
computer software.  
Angiogenesis on Matrigel: MMECs treated as above were plated on Matrigel reduced growth 
factor (Becton Dickinson Biosciences, Bedford, MA) coated 48-well plates in serum-free medium 
(SFM) or in presence of anti EphA3 or isotype Ab. After 18h, the skeletonization of the mesh was 
followed by measurement of mesh areas and vessel length in three randomly-chosen fields with the 
EVOS microscope at X200. 
 
Gene expression profiling and microarray analysis 
Total RNA from both siEphA3 and Control MMECs was extracted using Rneasy mini kit (Qiagen) 
and processed on Illumina HumanHT-12 v4.0 BeadChips according to the manufacturer's protocol 
and subsequently scanned with the Illumina HiScan. Data analyses were performed with 
GenomeStudio software (Illumina Inc.). Data was normalized with the quantile normalization 
algorithm, and genes were considered if the detection p-value was lower than 0.05. Statistical 
significance was calculated with the Illumina DiffScore. Only genes with a DiffScore ≤-30 and ≥30, 
corresponding to a p-value of 0.001, were considered as statistical significant. 
 
Mice studies 
Four-week-old NOD/SCID mice (Harlan Laboratories, Udine, Italy) were housed under specific 
pathogen-free conditions. All procedures were performed in the respect of the National and 
International current regulations (D.l.vo 27/01/1992, n.116, European Economic Community 
Council Directive 86/609, OJL 358, Dec. 1, 1987). Three groups (A-C) of five animals were 
injected sub-cutaneously with 10x106 of human JJN3 MM cell line. Starting from three days after 
tumor cell inoculation, group A received subcutaneously (s.c.) 75μg of anti EphA3 (chIIIA4) three 
times a week, group B received control isotype Abs and group C received PBS. Fourteen days after 
JJN3 inoculation, mice were sacrificed and autopsies were carried out. 
Tissiue Studies  
For immunohistochemistry tumor sections were immunostained with rat anti-mouse CD31 (clone 
SZ31; Dianova, Hamburg, Germany), mouse anti-ki-67 (Dako, Glostrup, Denmark), rat anti-mouse 
F4/80 (Caltag, Burlingame,CA, USA) Abs. Immunocomplexes were detected using the Bond™ 
Polymer Refine Detection Kit according to the manufacturer's protocol (Leica, Wetzlar, D), then 
sections were counterstained with H&E. Apoptosis was detected  by TUNEL staining with the 
ApopTag Plus Peroxidase In Situ Apoptosis Kit (Millipore, Billerica, MA) according to the 
manufacturer’s protocol.  
 
Results  
EphA3 is upregulated in MMECs vs MGECs and normal ECs 
EphA3 mRNA levels, measured by absolute RT-PCR, increases from ECs to MGECs, reaching the 
highest values in MMECs (Figure 1A). Accordingly, western blot and immunofluorescence showed 
a progressive increase of EphA3 protein from EC to MGEC to MMEC (Figure 1B-C). EphA3 
protein expression in MMECs was confirmed using flow cytometry; representative expression 
profiles are shown in Figure 1D.  EphA3 stained intensely and diffusely the MM microvessels and 
the plasma cells in MM BM biopsies (Figure 1E). 
Figure 1. Analysis of EphA3 expression in normal ECs vs MGECs vs MMECs. A. Absolute 
Real Time -PCR of  EphA3 mRNA copies /10*4 ABL copies as median + DS of 6 normal () and 8 
MGUS () and 35 MM subjects () respectively. p= 0,001 by One Way ANOVA and Kruskal-
Wallis test. B. Western blot of representative  2 normal, 2 MGUS and 5 MM subjects (β-
actin=loading control). EphA3 fold change of Optical Density (OD) as means +DS of 5 normal, 5 
MGUS and 26 MM subjects.   C. Confocal immunofluorescence of EphA3 in MMECs vs. MGECs 
vs. ECs. Corrected Total Cell Fluorescence (CTCF) as mean + DS of 26 MM and 5 MGUS and 5 
normal subjects. Pictures by confocal laser scanning microscope with 40X objective lenses. 
*=P<0.03 or better by Wilcoxon signed-rank. D) FACS analysis of EphA3 protein expression in 
MMECs from 2 representative patients. E. EphA3 immunohistochemical staining of BM biopsies 
from representative MM patients. EphA3 stains both neovessels (arrows) and plasma cells. 
Hematossilin/eosin staining (H&E) of BM biopsies is showed. Pictures by an Olympus 
photomicroscope (Olympus, Milan, Italy) with a CCD camera (Princeton Scientific Instr., 
Princeton, NJ, USA);  
 
Loss of EphA3 inhibits tubular morphogenesis in vitro  
In order to demonstrate the role of EphA3 in MMEC angiogenesis, we knocked down  its gene by 
silencing RNA (siRNA). In EphA3-siRNA MMECs the protein was reduced by over 80% vs 
untreated or non-targeted siRNA cells (Figure 2A). EphA3-siRNA did not affect cell viability nor 
induce apoptosis (data not shown), but impacted cell adhesion (-35%) and chemotaxis (-40%) 
(Figure 2B). The EphA3-siRNA MMECs seeded onto the Matrigel surface (which mimics the 
subendothelial basement membrane) gave no angiogenesis, i.e. it lost the arborized constitutive 
assembly with significant reduction in the vessel areas and length (Figure 2C).   
Figure 2. Effects on EC functions and angiogenesis in MMECs transfected with EphA3 siRNA 
(siEphA3). The cells were also transfected with non-targeting siRNA (Control siRNA) or 
lipofectamine only (Untreated) and analyzed after transfection. A. Western blot for knockdown 
analysis of EphA3 (β-actin=loading control). B. siRNA-transfected cells were tested for adhesion to 
fibronectin, chemotaxis and  (C) angiogenesis on Matrigel (quantified by vessel length and areas in 
the bottom panels)  and compared with control siRNA and untreated cells by the EVOS image 
software. Matrigel magnification=200X. Data are means  +SD of 18 MM patients. *P<0.03 or 
better and **P<0.01 or better by Wilcoxon signed-rank test.
The transcriptional profiles of EphA3-siRNA MMECs were compared with those of non-targeted 
siRNA cells. Among the significantly modulated genes (190 genes (Supplementary Table 1), we 
found downregulation of  the adhesion, migration and angiogenesis molecules RYK, JAM2,  VEGFA 
, FLNA, CD148  in  EphA3-siRNA MMECs. (Table 1) 
 
 
 
 
 
 
 
 
 
 
 
 
EphA3-specific antibody inhibits MMECs in vitro migration and tube formation  
To examine whether anti-EphA3 Ab (chIIIA4) affected the angiogenic functions of MMECs, we 
performed wound healing and tube formation assays. First, MMECs  treated with anti EphA3 were 
not affected for viability nor apoptosis (data not shown). MMECs in wound healing assay, 
decreasing the percentage of migrated cells from ≈ 90% (control) to 15% in the presence of  Ab 
anti-EphA3(chIIIA4). As expected, MMECs migration was not affected by an irrelevant Ab (Figure 
3A).  MMECs treatment with Ab anti-EphA3(chIIIA4) significantly inhibited the formation of tube-
like structures (Figure 3B). Overall, these results provided strong evidence of the antiangiogenic 
activity of anti EphA3, in vitro, affecting endothelial cell migration and tubulogenesis.  
Table 1. Down regulated genes in siEphA3 vs control siRNA MMECs 
ENTREZ GENE 
SYMBOL ID NAME FUNCTION FOLD CHANGE 
57124 CD248 Angiogenesis22 0,8 
2316 FLNA Adhesion, migration21 0,8 
7422 VEGFA Angiogenesis23 0,7 
58494 JAM2 Cell-cell adhesion24 0,7 
6259 RYK Focal adhesion25 0,3 
  
Figure 3. Characterization of anti angiogenic capability of anti EphA3-specific antibody . A. 
Analysis of migration of MMECs by wound healing assays in vitro. Representative photographs 
(4X magnification) taken 24h after scratching are shown. Cell migration was monitored over 24 h 
with 7,5 μg/ml of anti EphA3-Ab or an irrelevant Ab (Control) or in medium (Untreated) as 
indicated.  B. MMECs were cultured on standard Matrigel in the absence (Untreated) or presence of 
anti-EphA3 or an irrelevant Ab (Control). Representative microphotographs of tube formation after 
18 hours of culture (4X magnification) are shown. Quantification of lateral migration and tube 
formation (vessel length and areas) is shown at right panels. Anti EphA3 was assayed at least three 
times and the corresponding values (means ± SD) were represented. * P<0.01 versus control.  
 
Anti-EphA3 inhibits tumor xenograft growth 
Having demonstrated effects of anti EphA3 on MMECs in vitro, we next sought to assess the in 
vivo efficacy of anti EphA3 using a mouse model of human MM. 
First, we checked EphA3 expression in the MM cell lines such as MM1S, U266, RPMI8226 and 
JJN3. Our results indicated that JJN3 cells expressed the highest levels of EphA3, followed by 
MM1S, RPMI8226 and  U266 cells with a moderate expression of EphA3 (Supplementary Figure 
1A).  Furthermore, to study whether the treatment with anti-EphA3 antibody could directly affect to 
the tumor cell proliferation and survival, the MM cell lines were cultured in the presence of anti 
EphA3 antibody. No direct effect on tumor cell growth was observed in vitro in any of the MM cell 
lines (data not shown).  
We studied the effect of anti EphA3 on tumor growth by using JJN3 cells in NOD/SCID mice.  As 
shown in Figure 4A, anti EphA3 treatment significantly inhibited tumor growth.  Tumor developed 
was formed by round to oval cells showing a morphological range from mononuclear to 
occasionally multinucleated cells with prominent nucleoli and frequent mitotic figures (Figure 
4B(a). The tumor was supplied by a fairly developed microvascular network, as assessed by 
CD31immunostaining (b), and showed high proliferative activity, as revealed by Ki-67 
immunostaining (c) and low apoptotic index, as assessed by the TUNEL assay (d). Similar 
histologic (e) and immunohistochemical features (f, g, h) were observed in tumors developed in 
mice treated with control isotype Abs. By contrast, tumor masses developed in mice treated with 
anti-EphA3 Abs (i) were smaller in size (figure 4A) and showed foci of ischemic-hemorrhagic 
necrosis (N), in association with a significant (P < 0.05) reduction in the number of intact tumor 
microvessels (j).  The proliferative activity (k) was not significantly different from that observed in 
tumors from untreated or control isotype treated mice, while the apoptotic index was significantly 
(P < 0.05) increased (l) in comparison with tumors from both groups of mice (d and h). F4/80 
stained monocytes and macrophages were frequently found, particularly at the tumor edge, in close 
contact with apoptotic tumor cells evidences by aspects of nuclear fragmentation (inset in l). Taken 
together, these results demonstrate that anti EphA3 triggers in vivo inhibition of tumor growth, 
decreased angiogenesis, and increased MM-cell apoptosis. 
  
Figure 4. In vivo antitumor activity of the anti EphA3-specific antibody on MM xenograft 
mice. The SCID/NOD animals were injected subcutaneously with 10*106 of JJN3. Three days after 
cell inoculation, mice were divided in three groups of five mice and treated with control isotype or 
anti EphA3 antibody o PBS (Untreated). After fourteen days mice were killed, tumors removed and 
measured as described in the methods. A. Box plots represent the median volume of the masses 
removed from all the mice of each group . B. Morphological aspects of tumors developed in a 
representative untreated (a), control isotype Ab (e) or  anti-EphA3 Abs treated mice (ì). Round to 
oval neoplastic plasma cells with frequent mitotic figures (arrows) are showed. 
Microvascularization  was fairly developed in tumors from both groups of mice (b, f), tumor cell 
proliferation was fast (c, g) and apoptosis was scanty (d, h). By contrast, tumor masses developed in 
mice treated with anti-EphA3 Abs (i) showed foci of ischemic-hemorrhagic necrosis (N), in 
association with a defective microvascular supply (j). Tumor cell proliferation (k) was similar to 
that observed in control tumors (c, g), while apoptotic figures, frequently wrapped  by F4/80 stained 
monocyte/macrophages (inset), were clearly increased (l) in comparison with tumors from both 
untreated (d) and control isotype Ab treated (h) mice. (a-l: X400; inset in l: X1000). Left panel: 
Results are expressed as mean ± SD of CD31 positive microvessels per field; or Ki-67 or TUNEL 
positive cells/number of total cells (Proliferation Index and Apoptotic Index respectively) evaluated 
on formalin-fixed paraffin embedded  tissue sections by immunohistochemistry. * p< 0.001 One-
way ANOVA for comparisons between 3 groups; p < 0.05 Tukey-test compared with tumors from 
untreated mice; p < 0.05 Tukey-test compared with tumors from control isotype Ab treated mice. 
 
 
DISCUSSION  
MM cells strictly depend on the BM microenvironment for survival and disease progression. The 
activation/generation of endothelial cells and the consequent angiogenesis seems to be crucial in 
this process. The microenvironment consists of a ‘niche’ of BM stromal cells (BMSCs), including 
fibroblasts, osteoclasts (OCs), osteoblasts, vascular endothelial cells, lymphocytes and extracellular 
matrix (ECM). The crosstalk between MM and the BM niche, mediated by cytokines and adhesion 
molecules is critical for the homing of malignant cells to the BM, production of tumor survival 
factors and inhibition of osteoblastogenesis. A number of novel agents including thalidomide, 
lenalidomide and bortezomib have revolutionized the treatment of MM resulting in a significant 
improvement of the overall survival; their activity is through an anti-angiogenetic effect. Complete 
remission can be achieved but recurrence of the disease remains the main obstacle to cure. 
Considering the critical role of angiogenesis in sustaining the survival and proliferation of MM 
cells, there is a need of more effective drugs targeting the microenvironment and particularly the 
angiogenesis to improve the clinical outcome for MM patients.  
EphA3 receptor plays critical role in many solid tumors as well as hematological malignancies.  
Eph receptors and their membrane-bound ephrin ligands are involved in many biological processes 
including adhesion, cell migration and angiogenesis. Ephrin-B2 and the Eph receptors EphB3 and 
EphB4 are also present in vascular endothelium. During embryonic development, ephrin-B2 and 
EphB4 are expressed in arteries and veins, respectively, and are required for vascular remodeling 
during blood vessel maturation.26 However, the ephrin-A1 ligand and its EphA2 receptor are 
expressed in tumor angiogenesis.27 Antibody inhibition experiments show that Eph/ephrin signaling 
is required for angiogenesis to proceed.28 Further studies have shown that soluble EphA2-Fc and 
EphA3-Fc constructs inhibit tumor angiogenesis and growth in vivo,29 providing the first functional 
evidence for EphA receptor in the regulation of tumor angiogenesis. 
While their expression and function in normal adult tissues is limited, Eph and ephrin 
overexpression in human cancers often correlates with aggressive, invasive, and metastatic 
phenotypes. Eph/ephrin signaling activation can lead to different nearly opposite biological effects 
such as cell adhesion or cell repulsion. Data from the literature show that these opposite outcomes 
mediated by Eph/ephrin signaling are dependent on the Eph receptor signaling strength, cell type 
presenting the receptor and density of the receptor. Several variables direct the type of cellular 
responses.  
The role of EphA3 in MM has not been previously investigated. 
In this study we first showed that EphA3 is highly overexpressed in MM bone marrow derived ECs. 
The over expression was detected with different approaches at mRNA and protein level. 
Immunohistochemistry reaction in bone marrow biopsies from MM patients allows to identify the 
EphA3 in ECs and in hematopoietic cells.  Interestingly, we could detect EphA3 expression also in 
ECs from MGUS, although at lower levels, but not in normal ECs.  MMECs are analyzed ~30 days 
after harvesting from the BM, we suggest, tentatively, that changes in EphA3 gene and protein are 
stably acquired by these cells, with transition from MGUS (avascular phase) to MM (vascular 
phase). Perhaps these gene/protein changes are a consequence of genomic or epigenetic changes. 
Therefore, epigenetic regulation, such as changes in gene methylation, may play a dominant role in 
upregulating the expression of EphA3 in neoplastic cells and may be the result of already abnormal 
cell biology, supported by the fact that EphA3 expression is not regulated by methylation of the 
promoter in normal tissue.16 However, literature data show that little characterization of MM at the 
epigenetic level (for example gene methylation and acetylation) has been performed.30 
 
Angiogenesis is complex and tightly orchestrated multistep processes that involve several biological 
systems such as cell proliferation, migration and tube formation. Suppression at any step of these 
processes will inhibit the formation of new vessels.  We have demonstrated antiangiogenic effects 
of EphA3 knockdown (KD) in vitro at three levels: inhibition of adhesion, migration and tubular 
structure formation. This is consistent with previously reported data that showed EphA3 silencing 
prevents spreading of LK63 cells on fibronectin surface.31 Gene expression profiling showed that 
EphA3 KD inhibited some adhesion and pro angiogenic factor genes such as RYK, VEGFA, 
FLNA. The capacity of EphA3 to regulate these molecules by MMECs supports EphA3 as a 
regulator of angiogenesis. 22-25,32 
 
Interestingly, we obtained the same effects, a decreased migration and impaired capacity to form 
vessels in vitro by treating MMECs with an antibody targeting EphA3 (chIIIA4 mAb), in vitro.20 
chIIIA4 mAb targets a site closely adjacent to the heterotetramerization site on the N-terminal of 
EphA3’s extracellular domain adjacent to the ligand-binding site and has a high affinity for 
EphA3.33 The mechanism through which EphA3-specific antibody blocks MMECs adhesion and 
motility has not been investigated. Hence, it is possible that the anti-EphA3 antibody themselves 
may modulate EphA3 signaling  by forcing it into a conformation that interfere with the signal 
transduction cascade such as the antibody binding could modulate ligand oligomerization and 
clustering or impair reverse signaling.34 Additional work will be needed to conclusively address the 
precise mechanisms of these function-modulating antibody. 
 
Our in vitro data are clearly supported by the in vivo data.  
First, we demonstrated that all MM cell lines studied expressed high EphA3 levels. Interestingly the 
EphA3 mRNA copies are higher than those measured in MMECs. Therefore EphA3 also becomes 
potential target in cancer cells.  
Treatment of NOD/SCID mice bearing the JJN3 MM cell line with chIIIA4 mAb resulted in an 
effective inhibition of tumor xenograft growth. Immunohistochemistry analysis performed on tumor 
cells after treatment with chIIIA4 mAb clearly show that apoptosis was significantly increased in 
tumors treated with chIIIA4 mAb, whereas cell proliferation was not affected; the increased 
apoptosis over similar proliferation rates may account for the observed reduction in tumor growth in 
treated mice. Tumor xenografts showed a dramatic reduction in the number of blood vessels 
indicating that anti-EphA3 antibody mediated angiogenic suppression.  Interestingly, in the tumor 
after anti EphA3 treatment we observed a macrophage infiltration (insert in figure 4B) that could be 
responsible for an antibody-dependent cellular phagocytosis (ADCP).35 In fact, anti-EphA3 
antibody failed to inhibit the growth of cultured MM cell lines and primary MMECs (data not 
shown) in vitro, consistent with the hypothesis that anti-EphA3 affect tumor growth through a 
killing cell mediated mechanism rather than through inhibiting tumor cell proliferation per se. 
Therefore, the observed induction of apoptosis would be consequence of eliminating blood vessels. 
The effect of IIIA4 in vivo against EphA3 using mouse xenograft models of LK63 pre-B ALL, 
HEK293 cell line and SK-MEL28 melanoma cell lines was assessed. Rapid internalization of the 
monoclonal antibody is observed on administration of IIIA4 in mice tumor xenograft models and 
the mouse leukemia model.20 
 
Clinical and pre-clinical studies suggest that some therapeutic monoclonal antibodies, such as 
trastuzumab and rituximab may also enlist immune effector cells to attack and kill tumor cells by 
cytotoxicity (ADCC) and phagocytosis (ADCP). 36,37 Actually, IIIA4 has been modified using 
antibody Humaneering™ technology to produce KB004, which has now in multi-center open-label 
Phase 1 trial, (http://clinicaltrials.gov/ct2/show/NCT01211691) in patients with EphA3-positive 
hematologic malignancies including chronic myeloid leukemia (CML), acute myeloid leukemia 
(AML), acute lymphoblastic leukemia (ALL), myelodysplastic syndromes (MDS) who are refractory to, 
have failed, or have not received standard-of-care treatment. KB004 induces apoptosis of malignant 
cells through different mechanisms, mainly a immune effect induced by ADCC.38 
In summary, we have identified EphA3 as potential target in MM and described the initial 
characterization of anti-EphA3 that represents a new approach to target tumor and angiogenesis for 
MM treatment and, possibly, other angiogenesis-dependent pathologies. In the future, it will also be 
of interest to investigate whether anti EphA3 antibody can complement or synergize with other 
established anti angiogenic agents.
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